



REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,
Madhapur, Hyderabad - 500 081, Telangana, INDIA.
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com
CIN: L24110TG1991PLC012471

Dated October 21, 2019

To,
National Stock Exchange of India Limited,
BSE Limited
Symbol: GRANULES Scrip Code: 532482

Sub: Granules India Limited received US FDA approval for Fexofenadine Hydrochloride Tablets

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

The US Food & Drug Administration (US FDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules India Limited for Fexofenadine Hydrochloride Tablets USP, 60 mg and 180 mg (OTC). It is bioequivalent to the reference listed drug product (RLD), Allegra Allergy Tablets, 60 mg and 180 mg, of Sanofi-Aventis U.S. LLC.

This is for your information and dissemination to the members

Thanking you.

Yours faithfully

FOR GRANULES INDIA LIMITED

J. Chaitanya

**CHAITANYA TUMMALA
COMPANY SECRETARY
COMPLIANCE OFFICER**

